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Epstein–Barr virus (EBV), originally discovered through its association with
Burkitt lymphoma, is now aetiologically linked to a remarkably wide range
of lymphoproliferative lesions and malignant lymphomas of B-, T- and
NK-cell origin. Some occur as rare accidents of virus persistence in the B
lymphoid system, while others arise as a result of viral entry into unnatural
target cells. The early finding that EBV is a potent B-cell growth transforming
agent hinted at a simple oncogenic mechanism by which this virus could
promote lymphomagenesis. In reality, the pathogenesis of EBV-associated
lymphomas involves a complex interplay between different patterns of viral
gene expression and cellular genetic changes. Here we review recent develop-
ments in our understanding of EBV-associated lymphomagenesis in both the
immunocompetent and immunocompromised host.
This article is part of the themed issue ‘Human oncogenic viruses’.1. Introduction: Epstein–Barr virus infection, virus-induced
lymphoproliferative diseases and the virus-associated
lymphomas
Epstein–Barr virus (EBV), a human gamma-1 herpesvirus, is widespread in all
populations and is carried as a latent asymptomatic infection in the vast
majority of individuals. Yet this same agent has powerful lymphocyte
growth-transforming ability and is aetiologically linked to a range of lympho-
proliferative lesions and malignant lymphomas [1]. Reconciling these two
different aspects of its behaviour is still a major challenge and requires a
deeper insight into the virus–host interaction.
To summarize current understanding of that interaction, primary infection
occurs by the oral route and leads (i) to local virus replication in the orophar-
ynx, involving lytic infection of mucosal epithelium and possibly also local B
cells, and (ii) to a virus-driven growth transformation of B cells in pharyngeal
lymphoid tissues, followed by a switch to a truly latent (antigen-negative) infec-
tion of the generalized memory B cell pool [2]. While these events are most
clearly seen during primary infection, they are also on-going during the sub-
sequent carrier state; thus, virus reactivating from the B cell reservoir is
thought to seed both new foci of replication in the oropharynx, leading to recur-
rent low level shedding of infectious virus, and new growth-transforming B cell
infections. A large body of evidence suggests that these lytic and growth-trans-
forming latent infections are subject to T cell-mediated immune control both
during primary infection and throughout life [3]. Thus, some primary EBV
infections are clinically manifest as infectious mononucleosis (IM), a febrile
illness characterized by hyper-expansion of both lytic and latent antigen-
specific T cell responses, while lower levels of these same responses persist as
memory T cells in the blood of all virus carriers and indeed are enriched as
tissue-resident populations in oropharyngeal lymphoid tissues where EBV
reactivations are thought to initiate [4,5].
Emphasizing the importance of such immune surveillance, individuals
with profound T cell impairment are at high risk of developing an acute
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
372:20160271
2
 on January 23, 2018http://rstb.royalsocietypublishing.org/Downloaded from EBV-positive B-lymphoproliferative disease (B-LPD). The
condition is classically seen in two immunocompromised set-
tings: (i) stem cell and solid organ transplant recipients
within the first year post-transplant when T cell function is
most suppressed (i.e. ‘early onset’ post-transplant LPD),
and (ii) HIV-positive patients who, in the era before highly
active anti-retroviral therapy (HAART), lost almost all T cell
function as they progressed to late stage AIDS. These
B-LPD lesions are frequently oligoclonal in origin and can
present at multiple sites, often developing within the central
nervous system in AIDS patients, leading to their designation
as ‘CNS lymphomas’. Cell growth appears to be directly
EBV-driven, making B-LPD an in vivo counterpart of the
B lymphoblastoid cell lines (LCLs) that arise when EBV
transforms B cells into permanent growth in vitro. Thus the
cells have a lymphoblastoid phenotype and express all 8
EBV latent proteins (the nuclear antigens EBNAs 1, 2, 3A,
3B, 3C and –LP and the latent membrane proteins LMPs 1
and 2), a form of infection referred to as Latency III [6].
While B-LPD’s frequent oligoclonality and polymorphic
appearance has deterred it being designated a true lym-
phoma, these lymphoproliferative lesions are resistant to
conventional cytotoxic drugs and, if untreated, grow to kill
the host. Fortunately, however, B-LPD remains highly anti-
genic and, in a post-transplant setting, will regress if
immunosuppression is reduced to allow a recovery of T cell
competence or if the disease is specifically targeted by adop-
tive transfer of EBV latent antigen-specific T cells.
Despite its potent antigenicity, EBV does successfully
infect and establish persistence in the naive host. This very
likely reflects the ability of some growth-transformed B cells
in vivo to downregulate latent antigen expression and
switch to a truly latent resting state, thereby escaping
immune detection. How this occurs is still poorly under-
stood, yet is relevant to the broader question of EBV
lymphomagenesis. Thus the fact that all B cell subsets are sus-
ceptible to virus infection yet long-term virus carriage is
restricted to memory B cells suggests that, initially, virus-
transformed cells either pass through a germinal centre
(GC) reaction (i.e. exploit the physiologic route whereby anti-
gen-activated B cells somatically mutate their
immunoglobulin (Ig) variable gene sequences and progeny
with improved antigen avidity are positively selected into B
cell memory) or actively generate a GC-like environment
and use individual latent cycle proteins at particular phases
to mimic the selection process [2]. Whatever the precise
details, it seems likely that EBV-infected B cells will enter/
re-enter GC reactions either during virus colonization of the
B cell system or during their subsequent persistence in the
memory pool, and that genetic accidents arising from this
normal process will contribute to the pathogenesis of the var-
ious EBV-positive B lymphomas [7].
The three major types of B cell malignancy linked to EBV
are the Burkitt, Hodgkin and diffuse large B cell lymphomas
(BL, HL and DLBCL). As illustrated in figure 1, these
tumours are thought to emanate from progenitor cells
arrested at distinct stages of GC transit or post-GC develop-
ment. Thus the Burkitt tumour and one subset of diffuse
large B cell tumours appear to be derived from germinal cen-
troblasts, whereas the other diffuse large subset and the
Hodgkin tumour have hallmarks of post-centroblast cells
that have been aberrantly selected later during GC transit.
These tumours’ relationships to the GC, inferred fromtumour cell phenotype and the presence of somatically
mutated Ig variable genes, emphasize the likely contribution
that genetic aberrations occurring within the GC have made
to tumour development. By contrast, the classical EBV-
driven B-LPD lesions seen early post-transplant are not GC-
derived but arise from virus-induced growth transformation
of either naive or mature memory B cells [8]. Recent work
suggests that naive B cell-derived lesions are more commonly
seen following stem cell transplant [9]. This may reflect the
fact that stem cell recipients often acquire or reacquire EBV
in the peri-transplant period when the repopulating B cell
pool is dominated by naive cells, whereas solid organ
(mainly kidney) graft recipients are typically already long-
term EBV carriers pre-transplant and disease may arise
from reactivation of existing memory cell infection. While
the early onset post-transplant B-LPDs are always EBV-posi-
tive, the three major EBV-associated lymphomas, and most of
their subtypes, can occur in EBV-positive or negative form.
This is particularly important because it suggests that, for
each tumour, there are at least two routes to a common
end, only one of which involves EBV infection. Indeed, com-
parisons between EBV-positive and -negative tumours of the
same subtype, especially with respect to the landscape of cel-
lular genetic change, has great potential to identify those
genomic changes that EBV infection renders redundant.
Table 1 summarizes the essential characteristics of the
EBV-associated B lymphomas and their subtypes, including
their degrees of EBV association, and their distinct patterns
of EBV latent antigen expression. For ease of presentation
these patterns are designated Latencies I (EBNA1 only), II
(EBNA1, LMP1 and LMP2) or III (full latent gene expression),
though it should be remembered that this classification is not
always hard and fast; in particular, tumours expressing
EBNA1 and low levels of LMP2 blur the boundary between
Latencies I and II, while different tumour types designated
Latency II can differ significantly in LMP1 and/or LMP2
protein levels (see table 1 footnote for further qualification).
These different latency programmes have clear implications
for the visibility of tumours to the T cell system and bring
into question the relationship between lymphoma risk and
host immune status. An absolute dependence upon
immune impairment is clear in the case of EBV-driven
B-LPD lesions, where EBV-transformed cells grow out oppor-
tunistically in the absence of T cell control. However, the
situation with respect to the three main EBV-associated B
cell lymphomas is more complex. On the one hand most of
these lymphomas, including those that are EBV-positive,
arise in individuals who are apparently immunocompetent,
implying the EBV-positive tumour’s independence from
virus-specific immune surveillance. On the other hand,
immune disturbance does affect lymphoma risk; thus, the
incidence of all three lymphomas, and the proportion of
those tumours that are EBV-positive, is increased in
HIV-positive individuals. A similar, but less marked, trend
is also seen in long-term transplant recipients. However, in
contrast to the acute B-LPDs, the heightened lymphoma
risk in these patient groups is not coincident with times of
peak T cell impairment and other factors must come into
play. Besides these B cell diseases, table 1 also lists the
surprising links between EBV, ostensibly a B-lymphotropic
virus, and both lymphoproliferative disease and malignant
lymphomas of T or NK cell origin. These less well studied
diseases bear witness to the rare occasions in which EBV
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Figure 1. Germinal centre origin of different B cell lymphomas. Circulating naive B cells migrate to the secondary lymphoid organs where, upon encountering
antigen, differentiate into centroblasts (CB) that undergo clonal expansion within the dark zone of the germinal centre. During proliferation, the process of somatic
hypermutation (SHM) introduces point mutations into the variable region of the Ig heavy and light chain sequences, thereby generating B cells with variant B cell
receptors (BCRs). Centroblasts subsequently differentiate into resting centrocytes (CC) and migrate to the light zone, where they are selected on the basis of antigen
affinity. Only B cells with advantageous BCR mutations that improve antigen affinity will interact with follicular dendritic cells (FDCs) and receive the appropriate T
cell survival signals necessary to evade apoptosis. Antigen-selected B cells can undergo further rounds of proliferation, mutation and selection by recycling to the
dark zone. B cells within the light zone can undergo immunoglobulin class switch recombination (CSR), before exiting the germinal centre, either as a memory B
cells or plasma cells. Due to the processes of SHM and CSR mediated by activation-induced cytidine deaminase (AID), germinal centre B cells are particularly
susceptible to genetic damage. Thus, aberrant AID activity contributes to the chromosomal translocations and mutations that give rise to the different B lymphomas
derived from B cells blocked at distinct stages of differentiation. PBL, plasmablastic lymphoma; PEL, primary effusion lymphoma.
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with serious consequences for the host as described in the
later sections of this review.
2. Burkitt lymphoma
Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin
B cell tumour that can be classified into three variants
based on clinical features and disease epidemiology [10].
Endemic BL (eBL), described by pioneering studies of
Dennis Burkitt, affects young children in regions of equatorial
Africa and Papua New Guinea, where it accounts for around
50% of all paediatric cancers. This high incidence form of
the disease classically presents as a jaw tumour and is
EBV-positive in almost every case [11]. From epidemiological
studies, it is clear that eBL is restricted to geographical
regions where Plasmodium falciparum malaria is holoendemic
and, coincidentally, where primary EBV infection occurs at a
young age [12]. By contrast, sporadic BL (sBL) occurs world-
wide, has a much lower incidence and affects children across
a slightly older age range. In the United States and Europe,
sBL is rarely associated with EBV but in other areas, notably
NE Brazil where BL incidence appears to be higher, EBV
rates can exceed 80% [13]. A third variant (more appropri-
ately termed ‘HIV-related BL’ than its usual description as
‘AIDS-related’) affects HIV-infected individuals. From
studies of the AIDS epidemic in the developed West, HIVinfection increases BL incidence by more than 100-fold
above that of the sporadic disease, and some 30–40% of
these tumours are EBV-positive. This led to BL being desig-
nated an AIDS-defining illness; importantly, however, the
tumour typically develops early in the course of HIV infec-
tion, coincident with symptoms of persistent generalized
lymphadenopathy and before circulating CD4þ T cell num-
bers begin to fall [14]. The contrast between this tumour
and the EBV-positive B-LPD lesions seen in late stage AIDS
is further emphasized by looking at incidence rates before
and after the introduction of highly active anti-retroviral
drug therapy in the late 1990s. Thus, while the numbers of
B-LPD lesions (including those recorded as primary CNS
lymphomas) have fallen dramatically in the post-HAART
era, the incidence of HIV-related BL has not changed [15–17].
Regardless of subtype and EBV status, all BL tumours are
morphologically and immunophenotypically similar, and
share a common gene expression signature resembling that
of centroblasts [18,19]. The tumours are composed of a mono-
morphic population of rapidly proliferating medium-sized B
cells characterized by the expression of IgM, CD10 and BCL6,
and bearing functionally rearranged and somatically mutated
Ig sequences indicative of a germinal centroblast origin. His-
tologically, they are largely devoid of normal infiltrating
lymphocytes with the exception of scattered phagocytic
macrophages, which give rise to the characteristic starry sky
appearance. Another key defining feature of all three BL
Table 1. Features of EBV-associated lymphomas.
disease cellular origin
% EBV
association
EBV
latencya latent EBV protein expressionb
B-lymphoproliferative disease
post-transplant naive or memory .90 III EBNAs 1, -2, -3A, -3B, -3C, -LP, LMPs 1, 2
HIV-related B cell .90
Burkitt lymphoma
endemic 100
sporadic GC centroblast 10–80 I EBNA1
HIV-related 30–40
classical Hodgkin lymphoma
nodular sclerosis 10–40
mixed cellularity 70–80
lymphocyte depleted post-GC centroblast 10–50 II EBNA1, LMPs 1, 2
lymphocyte rich 30–60
HIV-related .90
diffuse large B cell lymphoma
NOS 10 II/III EBNA1, LMPs 1, 2/all EBNAs, LMPs 1, 2
PAL post-GC centroblast 100 III EBNA1, -2, -3A, -3B, -3C, -LP, LMPs 1, 2
HIV-related 20–60 I/II/III EBNA1/EBNA1, LMPs 1, 2/all EBNAs & LMPs
rare immunocompromised B lymphomas
plasmablastic lymphoma plasmablast 75–90 I EBNA1
primary effusion lymphoma plasma cell 75–90 I EBNA1
T/NK lymphoproliferations
CAEBV T/NK/B 100
extra-nodal T/NK lymphoma T/NK 100 II EBNA1, LMPs 1, 2
aggressive NK lymphoma T/NK 100
aFor convenience, the patterns of EBV latent gene expression are frequently designated Latency I (EBNA1 only), Latency II (EBNA1, LMP1 and LMP2) or Latency
III (EBNAs1, -2, 3A, -3B, -3C, -LP, LMP1 and LMP2). However, it is now clear that disease-associated viral signatures may be more complex than originally
described. For example, Latency I and Latency II are now considered to represent opposite ends of a spectrum with variable degrees of expression of both LMP1
and LMP2. In addition, transcriptional studies have recently identiﬁed broader patterns of viral gene expression in which latently infected cells also express
varying levels of multiple lytic cycle transcripts. While these ﬁndings imply that a restricted set of viral lytic genes may be transcribed during an otherwise
latent infection, it remains unclear whether these additional lytic viral transcripts are translated or if they are expressed in every tumour cell.
bIn addition to latent protein expression, EBV-infected cells also express a series of non-coding viral RNAs. The EBER1/EBER2 transcripts and 44 mature miRNAs
derived from the BamHI A rightward transcripts (miR-BARTs) are present in all forms of latency, while 4 further BHRF1-derived miRNAs are expressed in Latency III.
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MYC oncogene on chromosome 8 and one of the three Ig loci,
most frequently the Ig heavy chain locus on chromosome 14
[20]. As a consequence of bringing the c-MYC gene under the
influence of the powerful Ig enhancer, BL cells constitutively
express high levels of MYC protein leading to uncontrolled
cell growth [21]. MYC overexpression also contributes to
maintaining the centroblast phenotype of BL tumour cells
by promoting a GC-like gene expression programme [22].
Importantly, however, studies from Em-MYC mouse models
suggest that MYC overexpression is not sufficient to drive
lymphomagenesis, in part, because high levels of MYC
induce a powerful p53-mediated apoptotic stress response
which ultimately must be overcome during tumourigenesis.
To counteract this apoptosis, the majority of BL cell lines
and around 30% of BL tumours carry TP53 mutations,
while BL tumours that retain wild-type p53 carry mutations
or epigenetic changes that lead to aberrant expression of thep53 regulator proteins, p19/ARF and MDM2 [23]. In
addition, the translocated c-MYC allele is itself frequently
mutated, thereby subtly altering its transactivation capacity
and reducing its ability to promote apoptosis.
As a result of several groundbreaking genetic studies, we
are now beginning to understand the additional oncogenic
events that cooperate with c-MYC deregulation during BL
pathogenesis [24–28]. To date, recurrent mutations have
been identified affecting genes related to cell cycle (e.g.
CCND3, CCNF, CDKN2A), apoptosis (e.g. MCL1) and chro-
matin remodelling (e.g. ARID1A, SMARCA4), as well as
genes implicated in other lymphomas (e.g. DDX3X).
Although the functional relevance of many of these changes
remains to be determined, studies have revealed that onco-
genic CCND3 mutations prevent the normal physiologic
regulation of cyclin D3 protein levels, leading to an accumu-
lation of cyclin D3 protein [24]. Notably the incidence of such
CCND3 mutations is reportedly much higher among sBL
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isms in these two subtypes [29]. Furthermore, up to 70% of
BL cases carry genetic lesions that stimulate the activity of
TCF3 (E2A), a transcription factor that functions as master
regulator of gene expression in GC centroblasts. One impor-
tant consequence of increased TCF3 activity is amplified
‘tonic’ (antigen-independent) B cell receptor (BCR) signalling
and activation of the pro-survival PI3K/AKT pathway,
which may be reinforced by additional mutations or the
expression of cellular miRNAs that abrogate PTEN
expression [29]. The critical role of PI3K signalling in BL
pathogenesis is further emphasized by the finding that acti-
vated PI3K cooperates with MYC during lymphomagenesis
[30]. Interestingly, this dependency of BL tumours on tonic
BCR signalling may explain why, even though one Ig allele
is involved in the c-MYC translocation, all BLs retain surface
Ig expression from a second functionally rearranged allele.
While EBV is clearly not essential for the development of
BL, an aetiological role for virus infection is supported by the
finding that in EBV-positive cases every tumour cell harbours
monoclonal EBV genomes. However, there is still much
debate regarding the precise details of BL pathogenesis in
terms of the nature of the B cell initially infected with EBV,
whether EBV infection precedes or follows the c-MYC trans-
location, and which viral genes are involved at different
stages of the malignant transformation process [21,31,32]. In
this regard, viral gene expression in most EBV-positive BL
tumours is restricted to EBNA1, the non-coding EBER
RNAs and a cluster of 45 BART-miRNAs (table 1), with
LMP2 expression recently detected in a small subset of
tumours [17,33]. Since these viral gene products per se are
insufficient to induce B cell proliferation, it is proposed that
EBV has other accessory roles during BL pathogenesis. One
view is that EBV increases the survival of BL tumour cells fol-
lowing the c-MYC translocation event, as evidenced by the
original finding that EBV-positive BL cell lines are more
resistant to apoptosis than isogenic EBV-negative counter-
parts [34]. However, there is still no clear consensus on the
mechanism underpinning this observation, with some
reports attributing these effects to the oncogenic EBER
RNAs [35] while others suggest roles for EBNA1 and the
BART-miRNAs. In this regard, EBNA1 has recently been
shown to deregulate multiple cellular genes implicated in B
cell survival [36,37] and may prevent cell death through inter-
actions with host proteins such as the anti-apoptotic protein
survivin [38] and the p53-regulator USP7 [39]. In recent
years, attention has switched to identifying potential func-
tions for the multiple BART-miRNAs. There is now strong
evidence that these viral miRNAs are not only critical for
optimal EBV-induced B cell growth transformation [40], but
also play a key role in maintaining the BL phenotype [41–
43]. However, with the notable exception of caspase-3
[41,44], few direct targets of EBV BART-miRNAs relevant
to BL survival have been identified to date.
An alternative (but not mutually exclusive) scenario is
that EBV promotes the likelihood of a c-MYC translocation
event within a GC B cell as a result of aberrations during
somatic Ig gene mutation and subsequent Ig class switch
recombination (see figure 1 legend). This is supported by
the finding that activation-induced cytidine deaminase
(AID), the enzyme that mediates both of these processes,
also promotes the generation of Ig/c-MYC translocations
[45]. Notably EBV infection induces AID activity [46],although a recent study concluded that this effect is mediated
by EBNA3C [47], a viral gene product not usually expressed
in BL tumours. One possible explanation to this paradox is
that early BL progenitors resemble EBV-transformed B lym-
phoblastoid cells (i.e. Latency III infection), and that the
subsequent transition to a more restricted Latency I pattern
seen in the final tumour occurs after the c-MYC translocation
and acquisition of additional compensatory genetic changes
[21,31]. Consistent with this idea are recent data suggesting
that activation of c-MYC transcription by the viral transacti-
vator EBNA2 predisposes the upstream c-MYC enhancer
region to AID-induced double-strand DNA breaks [48].
Holoendemic malaria, which is tightly associated with the
African endemic form of the disease, has also been shown
to induce AID activity while simultaneously increasing the
number of EBV-infected cells within the GC [49,50]; these
observations thus provide the first mechanistic link to explain
how malaria co-infection predisposes EBV-positive B cells to
acquire a c-MYC translocation. Likewise, as discussed else-
where [51], the early stages of HIV infection are associated
with persistent generalized lymphadenopathy, reflecting a
huge expansion of GC activity within lymphoid tissues,
and a shift towards a higher EBV load in the B cell system.
Respectively, these two factors likely underpin the marked
increase in BL incidence seen in HIV-positive cohorts in Wes-
tern countries and (compared to the low EBV-association
rates shown by sBL in these areas) the much higher pro-
portion of these HIV-related tumours that are EBV-positive.
Despite these recent advances, our understanding of BL
pathogenesis remains incomplete and, in particular, it is
unclear whether BL variants may arise by different pathoge-
netic routes. In this regard, eBL and sBL differ in the detailed
anatomy of Ig/c-MYC breakpoints [52], in the frequency and
pattern of Ig mutations [53] and in their gene expression pro-
files [54], implying that EBV-positive and negative forms of
the disease may originate from GC B cells at subtly distinct
stages of maturation. There are also differences in the muta-
tional landscape between eBL and sBL cases [29], and, as
recently reported, between BL tumours carrying different
EBV strains [55] suggesting that EBV compensates for the
lack of certain cellular mutations. However, further studies
will be required to determine the functional significance of
the above differences.
3. Hodgkin lymphoma
On the basis of distinct morphological and clinical features,
Hodgkin lymphoma (HL) can be divided into classical HL
(cHL), which accounts for the majority of cases, and nodular
lymphocyte predominant HL (NLPHL) [10]. Since NLPHL is
rarely EBV-positive, here we will focus on cHL where the link
with EBV is well established. As shown in table 1, cHL can be
further subdivided into four histological subtypes: nodular
sclerosis, mixed cellularity, lymphocyte depleted and lym-
phocyte rich [56], of which the first two subtypes account
for approximately 90% of all cHL cases. A common feature
of all four subtypes is that the neoplastic Hodgkin and
Reed-Sternberg (HRS) cells account for only 1–2% of the
tumour mass [57]. This paucity of HRS cells has hindered
both the clarification of their cellular origin and the identifi-
cation of genetic lesions that contribute to HL pathogenesis.
The remaining cells comprise a non-neoplastic cell infiltrate
composed of T cells, B cells, macrophages, eosinophils and
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tumour microenvironment and the malignant HRS cells con-
tributes to the growth, survival and immune escape of the
tumour [58]. The proportion of cHL cases associated with
EBV varies dramatically with age, gender, ethnicity, country
of residence and histological subtype [59]. EBV association
rates in developed countries range between 30% and 50%,
but much higher rates have been reported in developing
countries. EBV-positive cases are more prevalent in children
under 10 years and adults over 80 years, and are usually
associated with the less common mixed cellularity and lym-
phocyte-depleted subtypes. Given the association between
cHL and infectious mononucleosis, cHL arising in children
and young adults may be a rare consequence of primary
EBV infection, while the peak in older adults may be attribu-
ted at least in part to senescence of EBV immunity and an
increasing EBV load.
Particularly interesting in this regard are the data from
HIV-infected cohorts. Even though HL is not an AIDS-defin-
ing illness, the incidence of cHL is 10-fold higher than in the
general population, and essentially all of that increase
involves EBV-positive tumours of mixed cellularity or lym-
phocyte-depleted subtypes [60]. Just as with BL, the
development of HIV-related HL is not dependent on pro-
found T cell impairment; indeed cHL incidence among HIV
carriers has slightly increased after the introduction of
HAART [16]. Interestingly these tumours tend to arise some-
what later than HIV-related BL, in patients with relatively
modest reductions in CD4þ T cell counts. One possibility is
that partial CD4 suppression is sufficient to elevate EBV
loads in the B cell system while retaining the cytokine-
mediated T cell support through which CD4þ T cells may
contribute to cHL pathogenesis.
The presence of clonally rearranged and somatically
mutated Ig sequences in microdissected tumour cells reveals
that HRS cells are derived from GC or post-GC B cells [61].
However, HL is unique among B cell lymphomas in that neo-
plastic HRS cells have largely lost their B cell identity during
the process of malignant transformation. This phenomenon is
partly due to the repression of key B-cell-specific transcrip-
tion factors, such as TCF3 and EBF1, leading to a global
downregulation of B cell lineage gene expression [62,63].
Recent data suggest that re-expression of TCF3 induces apop-
tosis and cell-cycle arrest in cHL cell lines, indicating that
TCF3 is an important tumour suppressor gene in the context
of cHL [64]. This notion is supported by the results of a recent
genome-wide association study which identified a TCF3
polymorphism linked to an increased risk of HL [65].
Another hallmark of HRS cells is the loss of a functional
BCR as a result of epigenetic silencing of the Ig promoter,
repression of B cell transcription factors and loss of down-
stream components of the BCR signalling pathway [57,66].
In addition, around 25% of HRS cells carry destructive Ig
mutations that render the BCR non-functional [67]. While B
cells lacking a functional BCR arise through the normal
physiologic process of SHM, they would usually be rapidly
eliminated by apoptosis. Thus, HRS cells are likely derived
from ‘crippled’ pre-apoptotic GC B cells that have been
rescued by additional transforming events (figure 1)
A key pathogenic feature of HRS cells is the aberrant acti-
vation of numerous cell signalling pathways and transcription
factors that support the growth and survival of the tumour.
Extensive studies of cHL cell lines and primary biopsieshave identified two critical cell signalling pathways, NF-kB
and JAK/STAT, which are frequently deregulated in HRS
cells. Constitutive NF-kB signalling results from the expression
of multiple tumour necrosis factor (TNF) receptors, such as
CD30, CD40 and RANK, which are activated by the cellular
infiltrate surrounding the HRS cells [58]. NF-kB activity is
further enhanced by a variety of genetic lesions in HRS cells,
including amplification of the c-REL subunit, loss of inhibitory
IkB subunits and inactivation of TNFAIP [68]. JAK/STAT acti-
vation can be triggered by autocrine and paracrine growth
factors, including IL-7, IL9 and IL-13 [58] and these signals
can be intensified by mutations in the JAK/STAT pathway
[69]. However, our broader understanding of the transforming
events that contribute to HL pathogenesis remains limited, due
in part to the rarity of HRS cells within biopsy material,
although modern sequencing technologies combined with
improving methods of tumour cell selection are now begin-
ning to yield new insights [70,71]. One recent exome analysis
using flow-sorted HRS cells identified 99 recurrently mutated
genes; while some of these genes had been described in earlier
targeted sequencing studies, others identified novel genes not
previously linked to lymphoid malignancies. Notably, truncat-
ing mutations of beta-2-microglobulin (B2M) were strongly
associated with the nodular sclerosis subtype and younger
age at diagnosis [70]; however it remains controversial
whether disruption of B2M/MHC class I expression leads
to a better clinical outcome [70,72].
Although it has long been recognized that a proportion of
cHL tumours harbour monoclonal EBV genomes, we still do
not fully understand how the virus contributes to disease
pathogenesis. In this regard, EBV-infected HRS cells express
three viral proteins, EBNA1, LMP1 and LMP2, together
with the non-coding EBERs and BART miRNAs, the classical
Latency II pattern (table 1). Of these, the uniquely high levels
of LMP1 seen in EBV-positive HRS cells seem likely to be
essential in the pathogenesis of HL, since LMP1 activates
the NF-kB, JAK/STAT and PI3K cell signalling pathways,
and induces transcriptional changes in GC B cells that are
characteristic of HRS cells [73]. Another potential role for
LMP1 may involve suppression of the virus lytic cycle that
might otherwise lead to cell death. In in vitro models, the
switch from latency to virus replication in EBV-infected B
cells can be triggered by plasma cell differentiation or acti-
vation of BCR signalling. Recent data suggest LMP1 may
inhibit the former by disrupting the BLIMP1 transcription
programme necessary for terminal B cell differentiation
[74], while the latter may be blocked by the loss of a func-
tional BCR. By contrast, the contribution of LMP2 to HL is
less well understood. LMP2 signalling can provide a survival
signal through engaging the PI3K pathway and recapitulate
some of the gene expression changes seen in EBV-positive
HRS cells [75]. These changes are mediated by the N-terminal
ITAM motif of LMP2 which resembles the signalling domain
of the BCR, yet many of the downstream signalling com-
ponents necessary for both BCR and LMP2 signalling are
absent in HRS cells. Thus, one possibility is that LMP2
activity is only required in early HRS progenitor cells
which retain the downstream BCR signalling molecules, but
that LMP2 function is subsequently replaced by additional
genetic changes in the malignant HRS cells. However, given
that EBV-positive cases of HL are consistently LMP2-positive,
it is likely that LMP2 also has BCR-independent functions
that are important for maintenance of the HRS phenotype.
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appear morphologically and phenotypically similar, there is
increasing evidence that these two entities arise through
different pathogenetic routes. First, nearly all cases of cHL
carrying crippled BCRs are EBV-positive suggesting that
HRS precursors with such mutations can only survive and
undergo malignant transformation if infected with EBV
[76]. In this regard, EBV can rescue BCR-negative GC B
cells from apoptosis [77]. Second, TNFAIP3 mutations and
aberrant expression of multiple receptor tyrosine kinases
(RTKs) appear to be more common in EBV-negative cases
[78,79], indicating that EBV functionally substitutes for cer-
tain deregulated cell signalling pathways in HRS cells.
Finally, EBV infection has been shown to induce epigenetic
and transcriptional changes in primary GC B cells relevant
to HL [80]. Therefore, it appears that the aetiological role
for EBV is to provide the necessary signals required for the
growth and survival of the tumour by compensating for
the lack of critical cellular mutations, in particular the absence
of a functional BCR, in the HRS progenitor cells.02714. Diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common
type of high-grade non-Hodgkin lymphoma in adults,
accounting for up to 40% of cases globally. DLBCL is a hetero-
geneous disease, originally classified by the WHO in 2008 as
two molecular subtypes, based upon microarray-based gene
expression profiling [81]; germinal centre B-cell-like (GCB)
DLBCL and activated B-cell-like (ABC) DLBCL. Subsequent
analysis by next generation sequencing (NGS) has confirmed
that GCB and ABC DLBCLs have unique gene expression
signatures as well as different patterns of genetic mutation.
This has led to the further classification of the two major
subtypes of DLBCL into more clearly delineated diseases [10].
The 10% of DLBCLs that are EBV-positive (i.e. carrying
the virus genome in every malignant cell) constitute one par-
ticular group. Such tumours, typically lying within the
spectrum of ABC DLBCLs, were originally identified in
older patients and provisionally termed EBV-positive
DLBCL of the elderly [82,83], being defined as any EBV-posi-
tive monoclonal large B cell lymphoproliferation in an
immunocompetent patient greater than 50 years old. How-
ever, the disease has subsequently been re-classified as
DLBCL-NOS (‘not otherwise specified’) to take into account
the increasingly documented occurrence of EBVþ DLBCL
in younger immunocompetent patients [10,84,85]. The classi-
cal EBVþ DLBCL observed in the elderly is thought to arise
as a consequence of an age-related senescence of EBV-specific
T cell surveillance. The precise nature of the senescence-
associated defects in T cell immunity have not yet been
well defined, although a narrowing of the EBV-specific
TCR-Vb repertoire with reduced EBV-specific effector
memory CD4þ and CD8þ T cell numbers has been described
[86]. Consistent with reduced T cell immunity, these tumours
usually display a Latency III viral gene expression profile
[87], similar to that seen in the B-LPD lesions arising in
immunosuppressed transplant recipients or in late-stage
AIDS. In this regard, a recent study has indicated that the
EBV-encoded nuclear antigen EBNA3B, which is dispensable
for virus-driven B cell transformation, may actually attenuate
the oncogenic potential of EBV. Thus, inactivation ofEBNA3B promoted more aggressive DLBCL-like monomor-
phic tumours in mice reconstituted with a human immune
system. B cells infected with EBNA3B-deleted virus prolifer-
ated more rapidly and secreted less T cell chemoattractant
CXCL10, thereby reducing T cell recruitment at the tumour
site [88]. Notably, the same study also identified a number
of tumour-associated EBNA3B mutations although the func-
tional effects of these changes were not investigated. In
contrast, EBVþ DLBCL arising in younger patients usually
displays a Latency II gene expression profile, implying a
more complex multi-step pathogenesis involving some form
of immune evasion. Note that tumours of the ABC DLBCL
subtype generally have a worse outcome than the GCB sub-
type, and this is further exacerbated by EBV infection, with
EBVþ DLBCL-NOS cases showing a higher rate of extrano-
dal involvement, a more aggressive clinical course and
frequent refractory disease.
In molecular terms, EBVþ ABC DLBCL cells frequently
exhibit monoclonality by Ig gene rearrangements and by
analysis of EBV terminal repeat copy number. Just as in
EBV-positive BL and HL therefore, this strongly supports
involvement of EBV in the process of lymphomagenesis,
complementing the effects of cellular genetic changes. As to
the nature of those cellular changes, cytogenetic analysis of
EBVþ DLBCL-NOS has not identified characteristic abnorm-
alities, although copy number gains have been reported of
the c-MYC, BCL2 and BCL6 loci [89]. However, fewer chro-
mosomal alterations have been demonstrated for the EBVþ
ABC DLBCL than the EBV-negative counterparts, again sup-
porting a significant role for EBV in driving pathogenesis.
Exactly what that role might be remains to be determined
but there are important hints coming from the wider genetic
profiling of ABC DLBCLs. Biochemical studies have now
demonstrated the reliance of ABC DLBCL on genetic lesions
leading to constitutive NF-kB activation and chronic active
BCR signalling [90]. Constitutive NF-kB activation helps to
explain two key characteristics of these tumours, their plas-
mablastic phenotype and frequent resistance to
chemotherapy. Firstly, in the normal B cell differentiation
pathway, NF-kB stimulates its target gene IRF4, which in
turn transactivates PRDM1/Blimp-1 to induce full plasma
cell differentiation. While NF-kB signalling is constitutively
active, most ABC DLBCLs carry either inactivating point
mutations, deletions or epigenetic silencing of the PRDM1
gene, and consequently tumour cells are driven to accumu-
late at the plasmablast stage [91–93]. Secondly, NF-kB
dysregulates several pro-survival proteins, including
BCL-XL, cIAP1, cIAP2 and c-FLIP, potentially resulting in
chemotherapy-refractory disease [94]. In this context, the
EBVþ DLBCLs have an even more pronounced NF-kB
activation phenotype compared to the bulk of EBV-negative
DLBCLs, with nuclear expression of both the canonical and
non-canonical NF-kB pathways. This is thought to reflect
activation by LMP1, clearly expressed in most, if not all,
EBVþ DLBCLs, implying that the presence of EBV in these
tumours contributes to their refractory nature. Only the con-
stitutive NF-kB activation phenotype of this EBVþ DLBCL
subset has been examined while the role of chronic BCR sig-
nalling is yet to be resolved. To date, only one gene expression
profiling study has been performed specifically comparing
EBVþ with non-EBV-associated ABC DLBCL [95]. This ident-
ified high levels of expression of immune and inflammatory
gene pathways in the EBVþ tumours including, in addition
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signalling pathways. Importantly, in vitro studies of EBV infec-
tion of ABC DLBCL cell lines confirmed the enhanced
activation of NF-kB and increased phosphorylation of STAT3
was induced by EBV infection [95].
An unusual subset of DLBCLs comprises EBV-positive
tumours that occur in the context of long-standing chronic
inflammation. These tumours are also ABC DLBCL, derived
from late GC or post-GC B cells. These DLBCLs usually pre-
sent as a tumour mass involving body cavities, and
pyothorax-associated lymphoma (PAL) is the prototypic
form. PAL is associated with a history of chronic pyothorax
or chronic pleuritis due to the initiation of a therapeutic artifi-
cial pneumothorax for pleuropulmonary tuberculosis, which
was used in the past as surgical treatment for tuberculosis
[96]. The interval between the onset of chronic inflammation
and malignant lymphoma is usually over 10 years (median
37 years), with a median patient age of 65–70 years. Males
are more susceptible to this lymphoma, with a male to
female ration of 4 : 1. Other EBV-positive DLBCLs associated
with chronic inflammation and resembling PAL arise in the
context of metallic implants in bones and joints [97], of chronic
osteomyelitis, and of chronic venous ulcers [98,99]. The EBV
gene expression profile of PAL is usually Latency III. It has
been suggested that the EBV-transformed B cells at the site
of chronic inflammation are able to escape host immune sur-
veillance and grow out through several mechanisms, for
example involving production of cellular IL-10, an immuno-
suppressive cytokine [100,101], autocrine growth promotion
via the IL-6 and IL-6 receptor pathway [102], downregulation
of MHC class I expression [103] and mutation of immunodo-
minant T cell epitopes in EBNA3B [104]. In addition,
microarray analysis has identified interferon-inducible 27
(IFI27) as one of the most differentially expressed genes in
PAL compared to regular DLBCL [105]. Expression of IFI27
is in keeping with the role of chronic inflammation in this con-
dition since it is known to be induced in B lymphocytes
following stimulation with IFNa, although the role of IFI27
in lymphomagenesis has yet to be resolved.
DLBCLs that arise with increased incidence in HIV-
positive patients are another very instructive subset. In the
early years of the AIDS epidemic, reports of HIV-related
DLBCLs were dominated by tumours that were in effect
B-LPD lesions of late stage AIDS yet recorded as immuno-
blastic (i.e. ABC-like) DLBCL; accordingly, they were
described as predominantly (90%) EBV-positive with a
Latency III infection. Following the advent of HAART, the
incidence of such late-stage lesions has dropped to reveal
an underlying landscape of both non-GC-like and GC-like
centroblastic tumours that can appear at any stage of HIV
infection [106]. Current surveys show that, overall, some
30–35% of these DLBCLs are EBV-associated and, among
these, there is a greater spread of latency programmes than
was previously apparent [60]. Thus a recent study found
that 27/48 (56%) HIV-related DLBCLs of non-GC type were
EBV-positive with almost equal representation of Latency I,
Latency II and Latency III tumours, whereas in the larger
group of GC-like DLBCLs, 25/98 (25%) were EBV-positive
and there were predominantly of Latency I [17]. The
composition of HIV-related DLBCLs has therefore changed
post-HAART, but importantly the overall incidence and
EBV association rate of these tumours still remains signifi-
cantly higher than for DLBCL in the general population.A somewhat similar picture is now being recognized
among solid organ transplant recipients who, following an
initial period of high dose immunosuppression, are main-
tained on low level immunosuppressive therapy for many
years. While their risk of EBV-positive B-LPD is most acute
in the first year and proportional to the intensity of
immune suppression, these patients also carry an increased
risk of post-transplant lymphoma, particularly DLBCL,
throughout life [107,108]. Recent studies of such ‘late onset’
tumours suggest that 30–70% are EBV-positive, with
Latencies I, II and III all represented among the EBV-positive
subset [9,109–111]. There were also interesting differences
between the tumours based on EBV status. Thus the EBV-
positive DLBCLs had fewer genetic aberrations than their
EBV-negative counterparts, including fewer mutations affect-
ing NF-kB pathway genes, [109,111], had distinct
transcription profiles [110,112], and displayed markers of a
more immunosuppressive local environment [9]. Based on
such findings, it is clear that the pathogenesis of these ‘late
onset’ post-transplant tumours is more complex than that of
‘early onset’ B-LPD; however, where the virus is present, it
has influenced the genomic evolution of these tumours and
continues to influence the DLBCL phenotype.5. Other rare B lymphomas of the
immunocompromised state
For completeness, table 1 also includes two additional EBV-
associated tumours of B cell origin, plasmablastic lymphoma
(PBL) and primary effusion lymphoma (PEL). Both are rare
malignancies that were first recognized in late-stage AIDS
patients [113,114] but have since been seen occasionally in
other heavily immunocompromised settings [60,115]. PBLs,
identifiable through a distinct plasmablastic phenotype, typi-
cally present in the oral cavity but can appear at other sites;
PELs present as lymphomatous effusions where (as in HL)
the malignant cells have the Ig genotype of post-GC B cells
but have downregulated B cell markers. In both cases, the
majority (75–90%) of tumours are EBV-positive with Latency
I infection predominant. However, the virus’ contribution to
the pathogenesis of these tumours is unclear. The question is
of particular interest in the case of PELs, tumours which are
consistently positive for the Kaposi sarcoma-associated her-
pesvirus (KSHV) genome and express KSHV latent proteins
[116]. Current evidence comparing EBV-positive and nega-
tive PELs shows that the virus does subtly influence the
PEL cell phenotype [117], and so EBV may accelerate
KSHV-mediated lymphomagenesis either by directly impact-
ing on cell growth and apoptosis pathways or, alternatively,
by facilitating the maintenance of latent KSHV infection.6. Epstein–Barr virus-associated T/NK cell
lymphoproliferative diseases and
malignancies
EBV is a B-lymphotropic virus that does not infect the T- and
NK-cell lineages as part of its natural life cycle in vivo. How-
ever, ectopic T and/or NK cell infection does occur on very
rare occasions, leading either to EBV-driven lymphoprolifera-
tions (EBVþ T/NK LPD), clinically manifest as chronic active
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malignancies such as extranodal NK/T cell lymphoma
(ENKTL) and aggressive NK leukaemia (ANKL). While
these frankly malignant lymphomas may arise de novo,
others develop from a scenario of chronic active infection.
Indeed, up to 25% of the CAEBV cases will progress to malig-
nancy. Due to the paucity of information on ANKL, here we
will discuss the T/NK associated LPDs and malignancies,
with particular emphasis on CAEBV and ENKTL..org
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CAEBV is usually described as a chronic disease of childhood
and young adulthood where patients exhibit persistent IM-
like symptoms including fever, hepatosplenomegaly, persist-
ent hepatitis and extensive lymphadenopathy. This is
coupled with elevated EBV DNA load in the peripheral
blood mononuclear cells, histological evidence of organ
infiltration with EBV-infected cells and high concentrations
of pro-inflammatory cytokines in the blood. Although
CAEBV is usually considered a chronic disease, many
patients develop severe, often fatal complications including
multi-organ failure, digestive tract ulceration/perforation,
and haemophagocytic lymphohistiocytosis (HLH), in addition
to the risk of progression to T/NK malignancy.
Worldwide, CAEBV exhibits a strong ethnic and geo-
graphical predilection with the highest frequency of cases in
East Asia and in native populations of Central/South Amer-
ica and Mexico, themselves of Asian origin. The majority of
cases occur in children and young adults of either sex with
a mean onset of 11.3 years [118]. The frequency of CAEBV
arising from T cell versus NK cell infection is roughly
equal, but there are some clinical differences. Thus NK cell
CAEBV is usually milder and slowly progressing, though
with a surprisingly higher viral load [119], whereas T cell
CAEBV is more severe and rapidly progressive with a
higher incidence of hepatomegaly and lymphadenopathy
[120]. It remains unclear why this should be. Interestingly,
the number of cases of CAEBV in adults appears to be
increasing, perhaps because of greater awareness among clin-
icians; adult cases predominantly (87%) arise from T cell
infections and are often rapidly progressive.
The first case of CAEBV was described in 1978 yet its
pathogenesis is still poorly understood. Monoclonality of
the lymphoproliferative lesion by cellular and EBV terminal
repeat markers [121,122] strongly suggests its origin from a
single EBV-infected cell. However, no consistent mutations
or chromosomal aberrations have been identified in studies
to date [123–125]. The infected cells exhibit a Latency II
viral gene expression profile (table 1), including the newly
identified LMP2-TR transcript [126]. Despite this expression
of viral antigens, the infected cells appear to evade immune
surveillance and/or profit from impaired surveillance
in vivo. Many patients exhibit impaired NK cell and EBV-
specific CTL activity [124,127], but it is unclear if this is a
cause or consequence of the disease process. A consistent fea-
ture of CAEBV is the elevated plasma levels of both pro- and
anti-inflammatory cytokines, including interleukin (IL)-1b,
interferon (IFN)-g, IL-10, IL-13, IL-15, TNF-a and transform-
ing growth factor (TGF)-b [120,128]. Interestingly, the
cytokine profiles of T cell and NK cell CAEBV are surpris-
ingly similar, with the exception of IL-13 which is
significantly higher in NK cell cases. Given IL13’s involvementin IgE responses, this could help to explain the high serum IgE
levels and hypersensitivity to mosquito bites frequently
observed in NK cell CAEBV patients.
Individuals with the symptoms of CAEBV have also been
well documented in the US, but they differ from those
observed in East Asia in several respects. In many cases
the EBV infection is confined to B cells and less often involves
T or NK cells. The clinical course of the disease is milder and
the mean age of onset is later, at 19 years. Additionally, the
US cases exhibit a progressive loss of B cells, leading to hypo-
gammaglobulinaemia, as well as reduced NK cell numbers;
patients usually die of progressive B-lymphoproliferation or
incidental infection [129]. However, with the advent of whole
genome sequencing, some of these B cell CAEBV cases may
be ascribed to one or other of the many primary immunodefi-
ciencies that are now known to predispose to EBV pathology,
and therefore may require a separate classification [130,131].(b) Extranodal NK/T-cell lymphoma, nasal type
Extranodal NK/T-cell lymphoma (ENKTL) is a rare but
highly aggressive type of non-Hodgkin lymphoma (NHL)
associated with EBV. The lymphoma is marked by extensive
necrosis and angio-invasion and usually presents in extra-
nodal sites, predominantly within the upper aero-digestive
tract (nasal cavity, nasopharynx, paranasal sinus and
palate). Patients also present in extra-nasal sites including
skin, respiratory tract, gastrointestinal tract and testis. The
disease mainly occurs in adults (median age 40–50 years)
and predominantly in males. Interestingly, it follows a similar
geographical distribution to CAEBV, with greatest frequency
in East Asia, Central/South America and Mexico where the
tumour accounts for 7–10% of all NHLs and 20–30% of per-
ipheral T cell lymphomas. Comparatively, ENKTL only
accounts for up to 1% of North American or European
NHL cases [132]. ENKTL follows an aggressive clinical
course with an extremely poor prognosis, especially for
advanced disease. One of its outstanding features is an
inherent resistance to conventional anthracycline-based che-
motherapy, the overall 5-year survival rate of patients
treated for advanced disease being merely 6–25% [133–
137]. This resistance has been ascribed, at least in part, to
tumour cell expression of the Multi-Drug Resistance gene
(MDR1) encoding P-glycoprotein [138], and indeed the cur-
rent chemotherapy regimen has been designed accordingly.
However, P-glycoprotein is only expressed in a proportion
of ENKTL and next generation sequencing studies have
begun to identify numerous other factors that impact on
apoptosis resistance and disease progression.
Chromosomal abnormalities are commonly observed in
ENKTL and deletion of 6q21 is the most frequently observed
[139]. This 6q21 deletion leads to the loss of expression of sev-
eral tumour suppressor genes including PRDM1, ATG5,
AIM1, FOXO3 and HACE1 [140,141]. Interestingly, in malig-
nancies without the 6q21 deletion, these same tumour
suppressor genes are often subject to silencing by promoter
hypermethylation, highlighting a significant role for loss/
silencing of these genes in EBVþ T/NK cell malignancies.
Of particular note, loss of proteins such as FOXO3 and
HACE1 may contribute to the apoptosis-resistance pheno-
type of EBVþ T/NK LPD by, respectively, preventing the
induction of the pro-apoptotic BIM and PUMA, and by
impairing TNF-driven NF-kB activation. Several recent
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and STAT5B in up to 15% of ENKT lymphomas [142,143]
and activating mutations in JAK have been variously
observed [144]. Notably, all the STAT3 and STAT5B
mutations were located in the SH2 domain, which is critical
for STAT activation, and resulted in increased STAT phos-
phorylation, robust promotion of cell growth and cell
survival under IL-2 limiting concentrations.
The ENKTLs exhibit a Latency II gene expression profile
(table 1) with LMP1 expression being a defining feature of
these malignancies. Gene expression profiling of the tumour
has highlighted the activation of several oncogenic pathways
including NF-kB, MAPK and JAK-STAT [140]. Mirroring the
situation in several EBV-associated B lymphomas, constitu-
tive activation of NF-kB and its downstream pathways has
been proposed to be pivotal to the pathogenesis and
progression of T/NK cell disease. In that context, hypo-
cytokinemia is a hallmark of EBV-infected T cells, and this
has been associated with NF-kB activation driven by the
viral LMP1. In both in vitro and ex-vivo assays, when ectopi-
cally expressed in T cells, LMP1 recruits TRAF2/5 to its
cytoplasmic tail and thereby activates downstream NF-kB
signalling, resulting in suppression of the SAP/SH2D1A
gene expression at the transcriptional level and subsequent
upregulation of the Th1 cytokines TNF-a and IFN-g [145].
At the same time, LMP1 protects those T cells from TNF-a-
induced apoptosis by suppressing TNF-receptor expression
and by recruiting TRADD to the LMP1 cytoplasmic tail,
resulting in inhibition of the downstream caspase cascade.
One of the most intriguing and long-standing questions
regarding EBV-associated T/NK cell diseases concerns
EBV’s means of access into the T and NK cell lineages.
Mature T and NK cells are totally resistant to in vitro infection
and indeed lack the major receptor (CD21) through which the
virus infects B cells. Various lines of evidence are now begin-
ning to emerge which allude to the answer. We previously
demonstrated the presence of EBV in both the T cell and
NK cell populations in individuals with EBV-driven haemo-
phagocytic lymphohistiocytosis (HLH) [146] and, more
recently, CAEBV (unpublished), raising the possibility of
EBV infection of a common T/NK cell precursor. Subsequent
sequence analysis of T cell and NK cell CAEBV by the
Kimura group also identified individuals with EBV infection
of both T cells and NK cells. More importantly, they found
that both infected cell populations carried the same somatic
mutation marking their common origin, thereby providing
the strongest evidence yet for EBV infecting a common hae-
matopoietic T/NK cell precursor (17th International
Symposium on EBV and its associated diseases, Zurich
2016). Finally, studying the differentiation of human haema-
topoietic stem cells into T cells and NK cells in vitro, we have
demonstrated the expression of the CD21 receptor before the
point of T and NK lineage commitment and have successfully
infected these cells with EBV (C Shannon-Lowe, unpublished).
With this system, we can now begin to examine how EBV
drives the transformation of T cells and NK cells into LPD
lesions and ultimately into the malignancies described above.7. Summary
A brief glimpse back at table 1 is sufficient to appreciate the
unusually wide range of EBV-associated lymphomas, eachwith its own distinct pathogenetic pathway. While the
‘virus as innocent passenger’ argument cannot be completely
refuted, for each of these lymphomas the presence of an
active virus genome in every tumour cell constitutes strong
circumstantial evidence of an aetiological role. Furthermore,
where the same tumour type can occur in EBV-negative
form (as it can in BL, HL and DLBCL), cytogenetic and
increasingly whole genome analysis shows that where the
virus is absent the spectrum of cellular genetic changes is
wider and more complex than in the EBV-positive cases.
This argues that, on the multi-step path to malignancy, com-
plementation by the virus can render some genetic
aberrations redundant, an idea that is being progressively
reinforced as more is learnt about EBV’s engagement with
key cellular pathways governing cell growth and survival.
The differences in EBV gene expression between these
tumour types very likely reflect the virus’ different aetiologic
roles. In BL, where EBV latent protein expression is usually
restricted to the virus genome maintenance protein EBNA1,
the tumour phenotype appears to be dominated by indepen-
dent translocation/mutation events in the cell genome.
Crucially, these lead to hyper-expression of two proteins, c-
MYC and TCF3, with particular functions at key stages of
germinal centroblast proliferation. Strong evidence suggests
that EBV’s role is complementary to these effects; that is,
anti-apoptotic rather than growth-promoting. While the
anti-apoptotic effects of Latency I infection are subtle, they
nevertheless appear to be sufficient to give EBV-positive
GC cells an advantage in the evolution to malignancy [32].
Importantly, switching to an LMP1-positive Latency II or
III infection could offer greater protection; however such
cells would cease to proliferate because, as many in vitro
studies have shown [147,148], LMP1-driven signalling is
incompatible with the c-MYC-driven (NF-kB-silent, non-
inflammatory) gene expression programme that is crucial to
BL cell growth.
The contrast between BL and the other main EBV-associ-
ated lymphomas is therefore stark, even though virus-
mediated apoptosis protection remains a key feature. Thus,
in EBV-positive HL, DLBCL and the T/NKL, there is consti-
tutive expression of LMP1 leading to activation of NF-kB and
JAK/STAT signalling. These pathways are thought to be
influential in at least two respects: firstly, protection against
apoptosis as described, and secondly the activation of auto-
crine/paracrine signals that appear to promote tumour
growth and possibly also immune evasion. In this respect,
both HL and the T/NKLs are tumours with a particularly
heavy inflammatory environment, yet one that appears to
favour tumour progression. Importantly, this link between
inflammation and EBV-associated oncogenesis also extends
to EBV-positive tumours of epithelial origin, namely naso-
pharyngeal and gastric carcinoma, and its significance is
discussed further elsewhere [51]. Recent work on these carci-
nomas has also highlighted yet another activity of EBV that
may have general relevance but has yet to be fully explored
in the virus-associated lymphomas: that is the link between
EBV and the tumour epigenotype. Thus a striking finding
from the whole genomic analysis of gastric carcinomas was
that the 10% of these tumours that are EBV-positive form a
molecularly distinct subset with unusually heavily methyl-
ated epigenomes [149]. This chimes with studies in both B
cell and epithelial cell systems showing upregulation of the
cellular DNA methyltransferases DNMT1, DNMT3A and
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transient EBV infection of epithelial cells reportedly leaves
permanent epigenetic marks [152]. As we have seen in the
genesis of EBV-associated lymphomas, there are several
examples where the influence of key tumour suppressor
genes may be lost either by mutation or by epigenetic silen-
cing. If, for example, such silencing is more common in the
EBV-positive versus EBV-negative forms of B cell lymphoma,
this will reinforce the idea of EBV-induced epigenetic modifi-
cation as contributing to virus oncogenicity.
Finally, there is the role of EBV as a growth-transforming
agent. As is clear from the example of B-LPD, EBV can be
directly oncogenic in the context of the T cell-compromised
host. Whether these B-LPD lesions, which may be oligoclonal
or monoclonal, are truly malignant seems largely a semantic
argument since, if uncontrolled, they rapidly progress to kill
the host. Crucially however, whether such growth-transform-
ing events also represent necessary early stages of BL, HL or
DLBCL pathogenesis remains an open question. While the
connection appears distant in both BL and HL, it is closer
in the context of DLBCL. Thus, some DLBCLs (particularly
those arising in the elderly or in the setting of chronic inflam-
mation) appear to have acquired additional genetic
aberrations indicative of malignancy yet retain Latency III
infection, as if they had evolved directly from growth-transformed foci. Ironically, the relationship between pre-
neoplastic virus-driven LPD and lymphoma seems to be
clearest in the atypical context of T/NK lineage infection
where some CAEBV patients progress quite rapidly to EBV-
positive T/NK lymphoma, although clonal evolution from
T/NK-LPD lesion to lymphoma has not yet been formally
documented by molecular studies. Interestingly the T/NK-
LPD cells accumulating in the blood of CAEBV patients
display a Latency II form of infection and readily expand in
vitro with exogenous cytokine support. This suggests that
EBV can initiate proliferation in this unnatural target cell
type, albeit without using its classical B cell-growth transform-
ing programme, and that such cells are then at high risk of
further cellular genetic changes leading to malignancy. The
example only serves to re-emphasize the enormous versatility
of EBV as a lymphomagenic agent and the need for further
research to resolve the many as-yet-unanswered questions
posed by this virus and its fascinating links to human cancer.
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